Sabatolimab is a potential first-in-class monoclonal antibody targeting TIM-3, under investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). It demonstrates therapeutic activity by simultaneously targeting myeloid leukemia cells and immune cells, thereby exerting direct anti-tumor effects and potentially enhancing immune cell function.